Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zaid Farooq

Urology Sycamore, IL Doctor of Osteopathy

NPI 1437504768 CMS profile 7228710

1850 Gateway Dr Ste 203, Sycamore, IL 60178

Open in the dashboard

General payments

$10,842

91 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zaid Farooq of Sycamore, IL is reported in the CMS Open Payments database as having received $10,842 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,686 16
2024 General $6,455 11
2023 General $524 20
2022 General $1,708 32
2021 General $124 8
2020 General $106 2
2019 General $239 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zaid Farooq
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Zaid Farooq were reported at $1,686. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Zaid Farooq Urology median Middle half National median
2019 $239 $480 $147–$1,201 $163
2020 $106 $246 $87–$645 $114
2021 $124 $358 $111–$1,000 $132
2022 $1,708 $476 $143–$1,263 $149
2023 $524 $560 $168–$1,461 $160
2024 $6,455 $563 $170–$1,464 $164
2025 $1,686 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Coloplast Corp $6,982 22 payments
  2. Boston Scientific Corporation $1,875 13 payments
  3. Teleflex LLC $557 9 payments
  4. Laborie Medical Technologies Corp. $368 5 payments
  5. Axonics Modulation Technologies, Inc. $281 7 payments
  6. Pfizer Inc. $199 5 payments
  7. Astellas Pharma US Inc $93 3 payments
  8. Sumitomo Pharma America, Inc. $61 3 payments
  9. Endo Pharmaceuticals Inc. $54 3 payments
  10. Merck Sharp & Dohme Corporation $36 2 payments
  11. Other $335 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $5,000 1 payment
  2. Food and Beverage $3,170 78 payments
  3. Travel and Lodging $2,607 11 payments
  4. Education $65 1 payment
Products named General payments · program years 2019–2025
  1. Titan $1,982 21 payments
  2. TACTRA $935 3 payments
  3. Axonics $578 6 payments
  4. UROLIFT Interventional Urology $407 7 payments
  5. AMS 700 $258 5 payments
  6. XTANDI $227 7 payments
  7. Bulkamid $188 2 payments
  8. UROLIFT Interventional Urology $150 2 payments
  9. LithoVue $133 1 payment
  10. Optilume BPH Drug Coated Balloon Catheter $131 1 payment
  11. Other $1,115 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

790

Median for Urology: 1,053

Drug cost

$76,272

Median for Urology: $101,464

Branded share of claims

26.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 46 $29,736
Myrbetriq Mirabegron Brand 39 $26,224
Mirabegron Er Mirabegron Brand 18 $8,540
Estradiol Generic 50 $3,018
Tamsulosin Hcl Generic 267 $2,324
Trospium Chloride Generic 14 $1,678
Solifenacin Succinate Generic 51 $1,343
Silodosin Generic 16 $482
Potassium Citrate Er Potassium Citrate Brand 11 $458
Cephalexin Generic 54 $442

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$126,672

Of which drugs: $5,688

Medicare patients

339

Average age 75

Services billed

3,468

125 women, 214 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Chronic kidney disease 38%
Ischemic heart disease 34%
Diabetes 32%
Depression 31%
Atrial fibrillation 25%
Cancer 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 52 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record